Bonnie Fletcher Price

Bonnie’s practice focuses on patent litigation matters in federal district court and before the US Patent and Trademark Office (USPTO). She represents a diverse set of clients in the pharmaceutical, biotechnology and medical device industries. Bonnie’s litigation experience includes all aspects of pre-trial and trial district court practice, post-grant proceedings before the Patent Trial and Appeal Board (PTAB), and arbitration.

Bonnie’s pro bono practice includes representing veterans before the US Court of Appeals for Veterans Claims and asylum seekers in immigration proceedings and appeals before the Board of Immigration Appeals.

Prior to her legal career, Bonnie received a PhD in neuroscience and conducted research at the National Institute on Aging. Her research explored the cellular and molecular mechanisms underlying cognitive aging, focusing on epigenetic contributions to altered messenger ribonucleic acid (mRNA) and protein expression.

Bonnie’s recent representative experience includes:

• Sight Sciences, Inc. v. Ivantis, Inc. – Representing Sight Sciences in patent infringement litigation concerning the Hydrus Microstent implant for reduction of intraocular pressure in patients with mild-to-moderate primary open-angle glaucoma
• Biofer S.p.A. v. Vifor (International) AG – Representing Vifor in patent infringement litigation concerning the iron replacement product Injectafer
• Scilex Pharmaceuticals, Inc. et al. v. Aveva Drug Delivery Systems, Inc. et al. –Representing Scilex and co-plaintiffs in Hatch-Waxman litigation concerning their ZTlido product for the treatment of pain associated with post-herpetic neuralgia against abbreviated new drug application (ANDA) filers Aveva Drug Delivery Systems and Apotex
• Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. – Representing Samsung Bioepis in an inter partes review of patents concerning the treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
• Newron Pharmaceuticals SpA et al. v. Aurobindo Pharma Limited et al. – Represented Newron and co-plaintiffs in Hatch-Waxman litigation concerning Xadago (safinamide), an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes
• NeuroDerm Ltd. v. AbbVie Inc. – Represented NeuroDerm in an inter partes review of patents concerning levodopa/carbidopa formulations for continuous subcutaneous administration
• RSB Spine, LLC v. DePuy Synthes Sales, Inc. et al. – Represented RSB Spine in patent infringement litigation concerning various low-profile interbody plate spacer devices for spinal fusion
• RSB Spine, LLC v. Precision Spine, Inc. – Represented RSB Spine in patent infringement litigation concerning various low-profile interbody plate spacer devices for spinal fusion
• Journey Medical Corporation et al. v. Perrigo Pharma International DAC – Represented Journey Medical in Hatch-Waxman litigation concerning its Zilxi product for the treatment of rosacea, its Amzeeq product for the treatment of acne and its Qbrexza product for the treatment of primary axillary hyperhidrosis against ANDA filer Perrigo
• Journey Medical Corporation et al. v. Teva Pharmaceuticals, Inc. et al. – Represented Journey Medical in Hatch-Waxman litigation concerning Journey’s Qbrexza (glycopyrronium cloth) product for the treatment of primary axillary hyperhidrosis against ANDA filer Perrigo
• BioDelivery Sciences International, Inc. et al. v. Alvogen Pb Research & Development LLC et al. – Represented BioDelivery Sciences International in Hatch-Waxman litigation related to the Belbuca (buprenorphine buccal film) product for the management of pain against ANDA filers Alvogen Pb and Chemo Research*
• AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc. – Represented AstraZeneca in Hatch-Waxman litigation related to the Farxiga (dapagliflozin) product for improved glycemic control in adults with type 2 diabetes mellitus against ANDA filer Zydus*
• AbbVie Inc. v. Boehringer Ingelheim International GmbH – Represented AbbVie in Biologics Price Competition and Innovation Act (BPCIA) litigation related to Humira*

* Representation handled prior to joining Cooley

Speaking engagements

• Co-presenter, “Weathering the Storm: In Search of a Safe Harbor, Cooley at MassBio – Life Sciences IP Seminar, September 2023
• Co-presenter, “A CREATES Act Primer,” Cooley Rx series, May 2023

Publications

• Co-author, “Survey of the Arc Epigenetic Landscape in Normal Cognitive Aging,” Molecular Neurobiology, 2020
• Co-author, “Experience modulates the effects of histone deacetylase inhibitors on gene and protein expression in the hippocampus: impaired plasticity in aging,” Journal of Neuroscience, 2015
• Co-author, “A fine balance: regulation of hippocampal Arc/Arg3.1 transcription, translation and degradation in a rat model of normal cognitive aging,” Neurobiology of Learning and Memory, 2014
• Co-first author, “Reassessing the effects of histone deacetylase inhibitors on hippocampal memory and cognitive aging,” Hippocampus, 2014
• Co-author, “Normal Neurocognitive Aging,” in “Handbook of Psychology” (second edition), 2012
• Co-first author, “Age-Related Memory Impairment Is Associated With Disrupted Multivariate Epigenetic Coordination in the Hippocampus,” PLoS ONE, 2012
• Co-author, “No reduction in spinophilin-positive dendritic spine number or spinophilin protein levels in hippocampus of cognitively-impaired aged rats,” Neurobiology of Aging, 2008
• Co-author, “Selective cholinergic depletion of the hippocampus spares both behaviorally induced Arc transcription and spatial learning and memory,” Hippocampus, 2007
• Co-author, “Fornix lesions decouple the induction of hippocampal arc transcription from behavior but not plasticity,” Journal of Neuroscience, 2006
• Co-author, “Localization of endogenous and recombinant Na(+)-driven anion exchanger protein NDAE1 from Drosophila melanogaster,” American Journal of Physiology-Cell Physiology, 2001